Skip to content

Effect of a Unani drug in urinary infection.

Efficacy of a Unani pharmacopeial formulation in Waram Majra-i-Bawl in Women: A randomized standard controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/09/036138
Enrollment
66
Registered
2021-09-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N390- Urinary tract infection, site notspecified

Interventions

Intervention1: Unani pharmacopeia formulation Maghze Tukhme Khayarain (Cucumis sativus Linn) 5 daram (17.5g) Maghze Tukhme Kaddu (Cucurbita maxima) 5 daram (17.5g) Khurfa (Portulaca oleracea Linn) 4 d

Sponsors

Rajiv Gandhi University of Health Sciences
Lead Sponsor
National Institute of Unani Medicine
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Women diagnosed with clinical features such as Pusht me Dard, Usr al-bawl(dysuria), Bawl al-Dam (haematuria), Salsal al-Bawl(urgency), Hurqa alBawl(Burning), Taqtir al-Bawl (dribbling). Clinical features of uncomplicated urinary tract infection (uUTI) symptom as per UTI Assessment (UTISA) questionnaire

Exclusion criteria

Exclusion criteria: Women aged up to 18 years and over 60 years. Pregnant and lactating women. Those with complicated UTI such as those associated with pyelonephritis, urolithiasis, diabetes, neurological conditions or urinary tract obstructions. Women who will be catheterized. Hypersensitivity to nitrofurantoin and impaired renal function

Design outcomes

Primary

MeasureTime frame
Change in clinical features of urinary tract infection (urinary, frequency, urgency, dysuria or haematuria) assessed by UTISA questionnaireTimepoint: 9-10, 25 and 60 days from baseline

Secondary

MeasureTime frame
1. Change in Severity (e.g., intensity of pain, urgency, frequency and burning) of uncomplicated UTI.67 2. Change in quality of life (as estimated by validated outcomes measures SF-12). 3. Morisky Medication Adherence Scale-4 used to assess compliance with herbal medicine.Timepoint: 9-10, 25 and 60days from baseline

Countries

India

Contacts

Public ContactDR ARSHIYA SULTANA

National Institute of Unani Medicine

drarshiya@yahoo.com9740915911

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026